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Summary
Background A test-and-not-treat (TaNT) strategy has been developed to prevent people with high concentrations of 
circulating Loa loa microfilariae (>20 000 microfilariae per mL) developing serious adverse events after ivermectin 
treatment during mass drug administration to eliminate onchocerciasis. An important question related to cost and 
programmatic issues is whether annual retesting is required for everyone. We therefore aimed to investigate changes 
in L loa microfilarial densities during TaNT campaigns run 18 months apart.
Methods In this observational cohort study, we assessed the participants of two TaNT campaigns for onchocerciasis. 
These campaigns, which were run by a research team, together with personnel from the Ministry of Health and 
community health workers, were done in six health areas (in 89 communities) in Okola health district (Cameroon); 
the first campaign was run between Aug 10, and Oct 29, 2015, and the second was run between March 7, and 
May 26, 2017. All individuals aged 5 years and older were invited to be screened for Loa loa microfilaraemia before 
being offered ivermectin (unless contraindicated). L loa microfilarial density was measured at the point of care using 
the LoaScope. All those with a L loa microfilarial density of 20 000 microfilariae per mL or less were offered treatment; 
in the first 2 weeks of the 2015 campaign, a higher exclusion threshold of 26 000 microfilariae per mL or less was 
used. At both rounds of the intervention, participants were registered with a paper form, in which personal 
information were collected. In 2017, we also recorded whether each individual reported participation in the 2015 
campaign. The primary outcome, assessed in all participants, was whether L loa microfilarial density was above or 
below the exclusion threshold (ie, the criteria that guided the decision to treat).
Findings In the 2015 TaNT campaign, 26 415 people were censused versus 29 587 people in the 2017 TaNT campaign. 
All individuals aged 5 years and older without other contraindications to treatment (22 842 people in 2015 and 
25 421 people in 2017) were invited to be screened for L loa microfilaraemia before being offered ivermectin. 
In 2015, 16 182 individuals were examined with the LoaScope, versus 18 697 individuals in the same communities in 
2017. 344 (2·1%) individuals were excluded from ivermectin treatment because of a high L loa microfilarial density 
in 2015, versus 283 (1·5%) individuals in 2017 (p<0·0001). Records from 2017 could be matched to those from 2015 
for 6983 individuals (43·2% of the 2015 participants). In this cohort, in 2017, 6981 (>99·9%) of 6983 individuals 
treated with ivermectin in 2015 had L loa microfilariae density below the level associated with neurological serious 
adverse events.
Interpretation Individuals treated with ivermectin do not need to be retested for L loa microfilaraemia before the next 
treatment, provided that they can be re-identified. This adjusted approach will enable substantial cost savings and 
facilitate reaching programmatic goals for elimination of onchocerciasis in areas that are co-endemic for loiasis.
Funding Bill & Melinda Gates Foundation, Division of Intramural Research (National Institute of Allergy and 
Infectious Diseases, US National Institutes of Health).
Copyright Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the 
CC BY 4.0 license.
Introduction
Loiasis, which is often referred to as the eye worm 
disease because of the subconjunctival migration of 
the adult worm seen in some infected individuals, is a 
vector-borne parasitic infection. Loiasis is endemic to 
Africa from South Sudan in the east to southeastern 
Benin in the west, and to the northern border of Zambia 
and Angola in the south.1 Loa loa, the filarial parasite 
responsible for loiasis, is transmitted between humans 
through the painful bites of female tabanids (deer flies), 
Chrysops silacea and Chrysops dimidiata. In endemic 
areas, loiasis transmission occurs throughout the year, 
with peaks during the rainy seasons,2,3 and reinfection 
is common. Together with the long lifespan of adult 
worms—for instance, a female worm was removed 
from the eyelid of a patient 21 years after they visited a 
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loiasis-endemic area4—this continuous transmission 
contributes to the chronicity of infection. Adult worms 
live in the upper layer of the epidermis and in the 
conjunctival tissues. After mating with male worms, 
female worms produce embryos or microfilariae that 
circulate in the peripheral bloodstream with a diurnal 
periodicity. Some infected individuals can clear micro-
filariae from their bloodstream, whereas others harbour 
tens to hundreds of thousands of microfilariae per mL of 
blood, a condition sometimes termed hypermicro-
filaraemia. The reasons for this variability in response 
are not entirely understood but it could be due, in part, to 
a genetic predisposition.5,6 However, the major problem 
associated with high-grade L loa microfilaraemia first 
emerged in the context of the large-scale treatment with 
ivermectin to combat onchocerciasis in central Africa 
during the early 1990s. In 1997, data showed that serious 
adverse events (SAEs), sometimes with fatal outcomes, 
could occur in people with high concentrations of 
circulating L loa microfilariae after a standard dose 
(150 μg/kg) of ivermectin.7 These SAEs appeared to be 
triggered by the rapid and massive death of the ivermectin-
sensitive L loa microfilariae. Since then, imple mentation 
of ivermectin-based community treat ment for oncho-
cerciasis elimination has been halted or delayed in some 
foci of central Africa.
Between August and October 2015, we selectively treated 
people with ivermectin in an area of Cameroon where 
onchocerciasis and loiasis are co-endemic.8 To prevent the 
occurrence of SAEs, we used a test-and-not-treat (TaNT) 
strategy: we quantified L loa microfilaraemia in all 
consenting residents of the Okola health district who were 
aged 5 years or older (n=16 182) at the point of care. All 
individuals with more than 20 000 L loa microfilariae per 
mL, who were thereby deemed at-risk for SAEs, and 
those with contraindications to ivermectin (pregnant or 
breastfeeding women or those with a serious acute 
or chronic concomitant illness) were excluded from 
ivermectin treatment, but they were offered a single oral 
dose of albendazole 400 mg (unless this treatment was also 
contraindicated) for intestinal deworming. Individuals 
with more than 20 000 L loa microfilariae per mL 
were revisited after the campaign, to ascertain their 
onchocerciasis status by use of the standard skin-snip 
method. Those who were infected with Onchocerca volvulus 
received a 5-week daily treatment regimen with doxycycline 
(100 mg; unless contraindicated).
During this ivermectin-based TaNT campaign for 
onchocerciasis elimination, 95·5% of participants tested 
for L loa received ivermectin, and only 2·1% of 
participants were excluded for L loa densities of greater 
than this risk threshold.8 No SAEs occurred in any of the 
treated population. Because several ivermectin treatment 
campaigns are needed to achieve onchocerciasis elimi-
nation, an important question related to cost and 
programmatic issues is whether annual testing of 
the whole population for L loa microfilariae density 
is required. More specifically, do previously treated 
Research in context
Evidence before this study
In 2015, a large-scale evaluation of a test-and-not-treat 
strategy provided proof of concept that testing for high Loa loa 
microfilariae density before treatment prevents occurrence of 
severe adverse events after ivermectin treatment in areas that 
are co-endemic for onchocerciasis and loiasis. Although the 
strategy is considered promising, there is concern about the 
increased cost of this strategy relative to standard 
community-directed treatment with ivermectin. The cost 
difference over the programme lifespan is substantially 
dependent on whether people are retested every year. 
The objective of our study was to evaluate whether the L loa 
microfilariae density in a person not at risk of serious adverse 
events (those with a density of less than 20 000 microfilariae 
per mL) who received ivermectin increased above this 
threshold level 18 months after treatment. We searched 
PubMed and ISI Web of Knowledge with the search terms 
“(loiasis OR loase OR Loa loa) AND (ivermectin$) AND (trial OR 
therapeuti$)”, for work published in English or French before 
April 1, 2019. We also checked the references of all studies 
identified by these methods. A 2019 meta-analysis of previous 
trials of ivermectin on L loa microfilariae density indicated that, 
1 year after treatment, none of the 238 individuals with an 
initial L loa microfilariae density of less than 
20 000 microfilariae per mL were at risk of serious adverse 
events after ivermectin treatment. This finding suggested that, 
when eligible individuals are treated with ivermectin once, 
they can safely receive annual ivermectin treatment without 
testing.
Added value of this study
To our knowledge, our study is the largest to evaluate the 
development of individual Loa loa microfilarial density over 
two campaigns of community treatment with ivermectin for 
onchocerciasis. Our results suggest that individuals with an 
initial L loa microfilariae density of less than 20 000 microfilariae 
per mL who have received standard treatment with ivermectin 
as part of onchocerciasis elimination activities are unlikely 
(at an observed frequency of 0·03%) to have a microfilarial 
density associated with an increased risk of L loa-related serious 
adverse events if retreated within 18 months, and they could be 
treated again without being retested.
Implications of all the available evidence
Since 95% of participants can be safely treated with ivermectin 
during any given test-and-not-treat campaign, not having to 
repeat quantification of microfilarial density the following year 
would enable substantial savings in time and money.
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individuals require repeat testing? Data previously 
collected from 238 individuals with an initial L loa 
microfilariae density of less than 20 000 microfilariae per 
mL indicated that none was at risk of SAEs 1 year after 
receiving ivermectin.9
During a second TaNT campaign that was run in Okola 
between March and May 2017 (around 18 months after 
the initial campaign), we aimed to investigate changes in 
L loa microfilarial densities after the first treatment in 
2015, at the individual and community levels.
Methods
Study design and participants
In this observational cohort study, we assessed the 
participants of two TaNT campaigns for onchocerciasis. 
These campaigns, which were run by a research team, 
together with personnel from the Ministry of Health and 
community health workers, were done in six health areas 
(in 89 communities) in Okola health district (Cameroon); 
the first campaign8 was run between Aug 10, and 
Oct 29, 2015, and the second was run between March 7, 
and May 26, 2017. All individuals aged 5 years and older 
were invited to be screened for L loa microfilaraemia 
before being offered ivermectin (unless contraindicated).
Our study was authorised by the National Ethics 
Committee of Cameroon (number 2013/11/370/L/CNERSH/
SP) and approved by the Division of Operational Research 
at the Ministry of Health (number D30–571/L/MINSANTE/
SG/DROS/CRSPE/BBM). All volunteers pro vi ded written 
signed consent (or parental consent in the case of minors) 
before blood sampling and again before receiving treatment.
Procedures
L loa microfilarial density was measured at the 
point of care using the LoaScope.10 All those with a L loa 
microfilarial density of 20 000 microfilariae per mL or 
less were offered treatment; in the first 2 weeks of 
the 2015 campaign, a higher exclusion threshold of 
26 000 microfilariae per mL or less was used, as explained 
previously.8
The TaNT studies were not initially designed to provide 
longitudinal data. Nonetheless, at both rounds of the 
intervention, participants were registered with a paper 
form. Personal information about participants that was 
collected on this form included their full name, age, sex, 
phone number, and a household number assigned during 
an exhaustive census that was done a few weeks before the 
campaign. Our team did the censuses, with the help of 
community members from each village. In 2017, we also 
recorded whether each individual reported participation in 
the 2015 campaign.
All data collected on paper forms were entered into an 
electronic database using double-entry for quality control. 
An automated script was developed with Stata version 15.1 
to identify discrepancies between the two series of data 
entries from a given year, and all discrepancies were 
resolved by reference to the paper form. The 2015 data 
were matched to those from 2017 by use of participant 
name, age, village of residence and, when available, the 
individual barcode assigned to them in 2015. We assumed 
that names of individuals who participated in both 
campaigns might have been spelt differently, and we 
used a semi-automated algorithm to generate lists of 
likely matches. All matches with a high degree of 
certainty were validated manually. When the data forms 
were inconclusive, we contacted participants by phone 
for confirmation of their participation in the TaNT 
campaigns. This approach allowed us to define a sample 
of individuals tested in both 2015 and 2017.
Outcomes
The primary outcome, assessed in all participants, was 
wether their L loa microfilarial density was above or 
below the exclusion threshold (ie, the criteria that guided 
the decision to treat).
Statistical analysis
Unless otherwise stated, geometric means were used as a 
measure of central tendency. The prevalence and 
concentration of L loa microfilariae per mL of blood in all 
individuals tested in 2015 were compared with those of 
individuals tested in 2017 by use of χ² (for prevalence) or 
Mann-Whitney test (for intensity). For those participating 
in both campaigns, the McNemar’s test and Student’s 
t tests for paired samples were used to compare the 
prevalence and intensity of L loa microfilarial infection 
between 2015 and 2017. We also constructed transition 
matrices to represent the development of microfilarial 
densities on a semi-quantitative scale in the groups: 0, 
1–100, 101–500, 501–2000, 2001–10 000, 10 001–20 000, and 
more than 20 000 microfilariae per mL. All statistical tests 
were performed with Stata version 15.1.
Role of the funding source
The funders of the study had no role in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
In the 2015 TaNT campaign, 26 415 people were 
censused versus 29 587 people in the 2017 TaNT 
campaign. All individuals aged 5 years and older without 
other contraindications to treatment (22 842 people in 
2015 and 25 421 people in 2017) were invited to be 
screened for L loa microfilaraemia before being offered 
ivermectin. In 2015, 16 182 individuals were examined 
with the LoaScope, versus 18 697 individuals in the 
same communities in 2017. 344 (2·1%) individuals were 
excluded from ivermectin treatment because of a high 
L loa microfilarial density in 2015, versus 283 (1·5%) 
individuals in 2017 (p<0·0001; table 1). Records from 
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2017 could be matched to those from 2015 for 
6983 individuals (43·2% of the 2015 participants).
Based on the LoaScope results, the prevalence of L loa 
microfilaraemia decreased from 2015 to 2017: the con-
dition was found in 2901 (17·9%) of 16 182 individuals 
in 2015, versus 2981 (15·9%) of 18 697 individuals in 
2017 (p<0·0001). The geometric mean of positive L loa 
micro filarial densities decreased from 2825·00 micro -
filariae per mL (95% CI 2660·80–2999·22) in 2015, to 
1484·72 microfilariae per mL (1394·95–1580·27) in 2017 
(p<0·0001; table 1). This decrease in intensity of 
infection is reflective of a significant shift toward 
lower values in the frequency distribution of L loa 
microfilarial density (Mann-Whitney test, p<0·0001; 
figure 1).
The therapeutic coverage (people treated relative to the 
censused population) in the six health areas varied between 
50·8% and 65·5% in 2015 and between 60·5% and 78·0% 
in 2017. Of the 6983 individuals whose L loa microfilarial 
density was assessed with the LoaScope in both 2015 and 
2017, 6692 (95·8%) had received ivermectin in 2015, versus 
6798 (97·4%) in 2017 (table 1). The prevalence of L loa 
microfilaraemia in these treated individuals decreased 
from 2015 to 2017: the condition was found in 1161 (17·3%) 
of 6692 individuals in 2015, versus 872 (13·0%) of 
6692 individuals in 2017 (p<0·0001). The geometric 
mean of L loa microfilarial densities decreased from 
2550·30 microfilariae per mL (95% CI 2336·56–2783·59) 
in 2015, to 1123·82 microfilariae per mL (1017·06–1241·78) 
in 2017 (p<0·0001). By contrast, the prevalence of micro-
filaraemia remained unchanged in those who were not 
treated with ivermectin in 2015 (present in 173 [59·5%] of 
291 individuals in 2015 vs 173 [59·5%] of 291 individuals in 
2017), although the geometric mean of micro filariae 
density decreased in these individuals, from 16 516·4 
(13 170·0–20 713·1) in 2015, to 12 121·7 (9810·2–14 977·9) in 
2017 (p<0·00001).
General population Sample (n=6983)
2015 (n=16 182) 2017 (n=18 697) 2015 2017
Male to female sex ratio 0·93 1·00 0·97 0·97
Median age (IQR) 18 (11–42) 19 (11–40) 17 (10–47) 19 (12–49)
Loa loa microfilarial density, mf/mL (95% CI)
Arithmetic mean 1465·90 (1376·30–1553·49) 928·69 (861·89–995·48) 1426·62 (1295·41–1557·82) 712·64 (612·72–812·57)
Geometric mean of positive counts 2825·0 (2660·84–2999·22) 1484·72 (1394·95–1580·27) 2550·30 (2336·56–2783·59) 1123·82 (1017·06–1241·78)
Contraindication, n (%)
None 15 458 (95·5%) 18 100 (96·8%) 6716 (96·2%) 6816 (97·6%)
Loa loa density >20 000 mf/mL 344 (2·1%) 281 (1·5%) 134 (1·9%) 85 (1·2%)
Pregnancy 165 (1·0%) 250 (1·3%) 61 (0·9%) 57 (0·8%)
Ill health 215 (1·3%) 66 (0·4%) 72 (1·0%) 25 (0·4%)
Treated with ivermectin, n (%) 15 369 (95·0%) 17 994 (96·2%) 6692 (95·8%) 6798 (97·4%)
Refusals, n (%) 89 (0·5%) 104 (0·6%) 24 (0·3%) 16 (0·2%)
mf=microfilariae.
Table 1: Participants’ characteristics and frequencies of contraindications to ivermectin treatment in 2015 and 2017
Figure 1: Frequency distribution (A) and cumulative frequency distribution 
(B) of L loa microfilarial density
Data are in 16 182 individuals examined in 2015 (solid line) and in 
18 697 individuals examined in 2017 (dotted line).
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Among the 5531 individuals without detectable 
L loa microfilaraemia who received ivermectin in 
2015, 5274 (95·4%) individuals had no detectable 
microfilaraemia in 2017, whereas 257 (4·6%) individuals 
developed microfilaraemia in 2017, but all of these 
individuals had microfilarial densities of less than 
10 000 microfilariae per mL (table 2). Among the 
1161 microfilaraemic individuals in 2015 who received 
ivermectin, in 2017, 957 (82·4%) individuals showed a 
reduced density, 160 (13·8%) showed a similar density, 
and 44 (3·8%) showed an increased density.
Among the 118 individuals without detectable L loa 
microfilaraemia who were not treated with ivermectin 
in 2015, 109 (92·4%) individuals had no detectable 
microfilaraemia in 2017, and the remaining nine (7·6%) 
developed microfilaraemia in 2017; however, again, all of 
these individuals had microfilarial densities of less than 
10 000 microfilariae per mL (table 3). Among the 
173 individuals with microfilaraemia who were not treated 
with ivermectin in 2015, 67 (38·7%) individuals showed a 
reduced density, 94 (54·3%) showed a similar density, 
and 12 (7·0%) showed an increased density. Of the 
134 individuals who did not receive ivermectin in 2015 
because they had a L loa microfilarial density of more than 
20 000 microfilariae per mL, 81 (60·4%) had a L loa 
microfilarial density of more than 20 000 microfilariae 
per mL in 2017. 53 (39·6%) individuals with no 
contraindications in 2017 had microfilarial densities 
below the risk threshold and received ivermectin without 
incident (figure 2; table 4). Two individuals (0·03% of 
ivermectin-treated individuals in 2015) had a microfilarial 
density slightly more than 20 000 microfilariae per mL in 
2017 despite treatment: a man aged 75 years whose L loa 
density increased from 7294 microfilariae per mL to 
23 208 microfilariae per mL, and a man aged 45 years 
whose L loa density increased from 8051 microfilariae per 
mL to 20 499 microfilariae per mL
Two individuals who did not receive ivermectin 
treatment in 2015 because of pregnancy (density of 
14 105 microfilariae per mL) or ill health (12 569 microfilariae 
per mL) had a microfilarial density above the threshold 
18 months later (28 999 microfilariae per mL and 
29 109 microfilariae per mL).
6981 (>99·9%) of 6983 individuals treated with 
ivermectin in 2015 had a L loa microfilarial density below 
the exclusion threshold of 20 000 microfilariae per mL 
18 months later.
Discussion
The TaNT campaign that was run in the Okola health 
district in 2015 was successful in that more than 
15 000 inhabitants of an area that is co-endemic for 
onchocerciasis and loiasis were treated with ivermectin 
without SAEs. A second TaNT campaign, with systematic 
testing for L loa microfilaraemia, was initially planned to 
take place 1 year later, to concur with the usual schedule 
0 1–100 101–500 501–2000 2001–10 000 10 000–20 000 >20 000 Total
0 5274 11 201 38 7 0 0 5531
1–100 3 0 0 0 0 0 0 3
101–500 204 0 31 20 6 0 0 261
501–2000 179 1 54 40 14 0 0 288
2001–10 000 144 0 74 130 82 2 2 434
10 001–20 000 14 0 9 50 73 7 0 153
20 000–26 000 2 0 1 7 12 0 0 22
Total 5820 12 370 285 194 9 2 6692
Data are the number of individuals treated with ivermectin in 2015 within each recorded range of microfiliarial density (in microfilariae per mL) in 2015 versus that in 2017.
Table 2: Transition matrix of Loa loa microfilarial density in 2015 (left column) versus that in 2017 (top row), in individuals treated with ivermectin in 2015
0 1–100 101–500 501–2000 2001–10 000 10 000–20 000 >20 000 Total
0 109 0 6 2 1 0 0 118
1–100 0 0 0 0 0 0 0 0
101–500 6 0 1 2 3 1 0 13
501–2000 1 0 1 2 3 1 0 8
2001–10 000 0 0 0 3 8 0 0 11
10 001–20 000 0 0 0 0 3 2 2 6
>20 000 2 0 0 3 19 29 81 134
Total 118 0 8 12 37 33 83 291
Data are the number of individuals not treated with ivermectin in 2015 within each recorded range of microfiliarial density (in microfilariae per mL) in 2015 versus that 
in 2017.
Table 3: Transition matrix of Loa loa microfilarial density in 2015 (left column) versus that in 2017 (top row), in individuals not treated with ivermectin 
in 2015
See Online for appendix
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of repeated community treatments with ivermectin 
against onchocerciasis. However, field activities were 
delayed by 6 months for logistical reasons, and the 
second round was therefore conducted 18 months after 
the first.
Assessment of L loa microfilarial density during this 
second campaign showed substantial impact of the first 
large-scale treatment on the microfilarial reservoir of L loa. 
The notable drop in L loa microfilarial density was expected 
to some degree, based on data from a 2019 literature review 
and meta-analysis9 of the effect of ivermectin on L loa 
microfilariae up to 1 year after treatment. However, our 
study indicates that the effect of ivermectin remains 
18 months after the initial dose. A similar effect was seen 
in a community trial11 in an area neighbouring the Okola 
health district, which found reductions in L loa microfilariae 
1 year after ivermectin treatment that were comparable to 
those measured in our study 18 months after ivermectin 
distribution (appendix p 1).
The major finding of our study was that 99·97% of 
individuals treated with ivermectin in 2015 had a L loa 
microfilarial density below the exclusion threshold of 
20 000 microfilariae per mL 18 months later. Together with 
the observation that no individuals with microfilarial 
densities of less than 20 000 microfilariae per mL who 
were treated with ivermectin in all previous trials9 
(238 individuals) presented with a higher microfilarial 
count 1 year later, our findings suggest that individuals 
treated once with ivermectin could be safely retreated 
within 18 months without retesting. Although two 
individuals in our study who had microfilarial densities of 
less than 20 000 microfilariae per mL in 2015 had densities 
slightly greater than this value in 2017, it is important to 
recognise that the LoaScope threshold was deliberately 
chosen to be extremely conservative based on the currently 
available SAE data7,12–15 documenting neurological adverse 
events after ivermectin treatment only in individuals with 
densities of at least 50 000 microfilariae per mL. Thus, the 
two individuals whose counts increased to slightly greater 
than 20 000 microfilariae per mL in 2017 probably could 
have been safely treated with ivermectin without retesting.
Our study is unique in its scale and documentation of 
the stability and variability of L loa microfilarial density 
over time. L loa microfilarial density is generally considered 
to be very stable over time in untreated individuals.16–18 
This general trend was confirmed in our study, 
in which approximately 70% of the participants (including 
amicrofilaraemic and microfilaraemic indi viduals) who 
did not receive ivermectin in 2015 had similar microfilarial 
densities 18 months later (ie, they remained in the same 
category in the transition matrix; table 3). Despite this 
finding, our data suggest that retesting of individuals who 
did not receive ivermectin in the previous round is 
important, since 51 (38·1%) of 134 individuals excluded 
from ivermectin treatment in 2015 because of high 
microfilarial densities had densities of 20 000 microfilariae 
per mL or less in 2017 and they could receive ivermectin, 
Figure 2: Loa loa microfilarial density in our sample of 6983 individuals examined in 2015 and 2017
(A) Individuals treated with ivermectin in 2015. (B) Individuals not treated with ivermectin in 2015.
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Table 4: Transition matrix of contraindications to ivermectin in the sample in 2015 (left column) versus 
that in 2017 (top row)
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and two individuals, whose microfilarial density was below 
the threshold in 2015 but who were excluded because of 
pregnancy or ill health, had microfilarial densities that 
precluded ivermectin treatment in 2017. Among the 
ivermectin-treated individuals with microfilaraemia in 
2015, most (82·4%) people had decreased counts in 2017; 
only 3·8% moved into a higher category in the transition 
matrix, and only two people had densities of more than 
20 000 microfilariae per mL (table 2). Potential reasons for 
the variability in microfilarial densities include the diurnal 
periodicity of L loa microfilariae in the blood and resultant 
variation depending on the exact time of the blood draws; 
acquisition or attrition of fertile female worms; and 
alterations in host response after ivermectin treatment.19
The main limitation of our study was the relatively low 
number of individuals (only 43·2%) who could be 
definitively matched between the 2015 and 2017 campaigns. 
The main source of this problem was uncertainty 
surrounding the identity of the participants, due to no 
standardised spelling of certain names and inaccurate 
recording of age in the elderly population. Also, a high 
proportion of individuals participated in the initial TaNT 
campaign while visiting neighbouring villages (and thus 
could not be matched on the basis of village in 2017). 
Although every participant was given an individual card 
containing their name, phone number, result of L loa 
microfilarial density assessment, and treatment received, 
few people brought this card with them when they 
presented for retreatment in 2017. Despite this limitation, it 
is unlikely that individuals who participated in both rounds 
but whose records could not be definitively matched had a 
different response to ivermectin treatment than those who 
could be matched unequivocally, and the number of actual 
matched records (n=6983) was sufficient for statistical 
power and accuracy around the estimates.
Not having to retest everyone annually could have 
important implications for the costs and practical 
implementation of the strategy. In a neighbouring area of 
Cameroon, where the TaNT strategy was implemented in a 
pilot study20 by local health personnel and community 
volunteers (with oversight by the research team), the costs 
were estimated at US$9·2 per person tested. Notably, it 
was projected that, under programmatic implementation 
scenarios, these costs could be reduced to about $5 per 
person treated.20,21 If participation is high during the first 
round, far fewer people will need to be tested during the 
subsequent round. Indeed, about 95% of the participants 
from round N would not have to be tested during 
round N + 1. The extra cost of the TaNT strategy during 
subsequent years is likely to be much smaller than in the 
first round. After several years of TaNT—the duration of 
which remains to be determined—ivermectin-naive 
people could be tested and treated in a central health 
structure (health area or health district) whereas the rest 
of the population could be treated using the classic 
community-directed treatment with ivermectin strategy. 
This approach would lead to dramatic cost savings (eg, less 
time spent by health personnel for testing, lower costs for 
LoaScopes and capillaries).
Additionally, previously treated individuals could be 
retreated even in the absence of a so-called LoaScopist (the 
volunteer in charge of testing the L loa microfilariae density 
with a LoaScope), providing more flexibility in the 
implementation (ie, how and when people are treated) and 
possibly an increase in the number of people treated per 
day. These benefits require that people treated in the 
previous round can be re-identified easily and reliably. 
Although identification could theoretically be done using 
the individual card (containing their name, phone number, 
result of L loa microfilarial density assessment, and 
treatment received), most people in our study did not 
present the card during the second campaign. Treatment 
registers specifically designed for a 5-year follow-up, 
possibly including an identification key (picture, signature) 
could be used to improve the validity of treatment registers 
used during community-directed treatment with ivermectin 
campaigns. Alternatively, biometrics (fingerprint or iris 
scanning) could be used, as has been demonstrated for 
other public health applications.22
The populations living in areas in need of an alternative 
treatment strategy for elimination of onchocerciasis has 
been estimated, using mathematical projections, to be 
about 14 million in 2015, with the greatest number of 
individuals located mainly in the Democratic Republic of 
the Congo, but also in Cameroon, the Central African 
Republic, and Gabon.23 Additional onchocerciasis surveys 
should be done to refine those estimates. Strategies other 
than TaNT (such as selective treatment of people infected 
with onchocerciasis with doxycycline) could be considered 
in small communities with a very low onchocerciasis 
prevalence.
Assessment of L loa microfilaraemia in an endemic 
population 18 months after a large-scale treatment with 
ivermectin showed a notable reduction in the reservoir of 
L loa microfilariae, with microfilarial counts in all 
previously treated individuals below the level previously 
associated with neurological SAEs. On the basis of our 
results, we would argue that individuals treated with 
ivermectin during the preceding 18 months would not 
have to be retested for L loa microfilaraemia before 
receiving ivermectin. The reduced number of people in 
need of retesting would lead to huge cost savings and 
facilitate reaching programmatic goals for elimination of 
onchocerciasis in areas that are co-endemic for loiasis.
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